Match tier
Institution-verified
Presence
Current · Arkansas
Last published
2026
Sources
Institutional record
Refreshed
2026-08-15
K
Konstantinos Arnaoutakis
Sourced from institutional research profiles (UAMS TRI or ARA).
Researcher
Also affiliated: Tufts University (2009); BC Cancer Agency (2016); University of South Florida (2024); University of Arkansas Medical Center (2014); Welsh Government (2012–2014); St. Elizabeth's Medical Center (2008–2009); University of Bristol (2004); Central Arkansas Veterans Healthcare System (2016); Accurate Automation (United States) (2004); Winthrop Rockefeller Foundation (2014–2023); Cardiff University (2006–2011); University of Sheffield (2004)
Faculty Researcher
13 h-index
67 pubs
629 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Konstantinos Arnaoutakis' research focuses on cancer, particularly lung and colon neoplasms, and stem cell theory as it relates to cancer. He has investigated treatment patterns and outcomes for patients with ALK+ non-small cell lung cancer and explored the implications of stem cell theory for translational cancer research, drug development, and therapy. Arnaoutakis has also examined the application of genomic data science methods for analyzing rare tumor types and contributed to case reports utilizing genomics, pathomics, and radiomics. His work includes an analysis of a modified frailty index on perioperative morbidity and mortality following endovascular aortic aneurysm repair. Arnaoutakis has published 67 papers, accumulating 621 citations, and holds an h-index of 13. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Bhavesh Mohan Lal and Matthew A. Steliga.
Metrics
- h-index: 13
- Publications: 67
- Citations: 629
Selected Publications
-
Association Between Metabolic Syndrome and Prostate Cancer: A Systematic Review (2026)
-
DLL3-targeted therapy with tarlatamab in small cell lung cancer across lines of therapy: A systematic review of prospective and randomized clinical trials. (2026)
-
Incidentally Detected Pulmonary Carcinoid Tumorlet With Coexisting Carcinoid Tumorlet in the Mediastinal Lymph Node in a Patient With Lung Cancer (2025)
-
Optical imaging of treatment-naïve human NSCLC reveals changes associated with metastatic recurrence (2024)
-
Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice (2024)
-
Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC (2024)
-
Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care (2024)
-
An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics (2023)
-
PP01.55 Real-World Treatment Sequencing and Impact on Outcomes in ALK-Positive (ALK+) Non–Small Cell Lung Cancer (NSCLC) (2023)
-
Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench (2022)
-
Abstract 5038: Applying reproducible genomic data science methods for the analysis of a rare tumor type (2022)
-
Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative (2022)
-
Depression in lung cancer patients: A nationwide analysis. (2019)
-
Absolute lymphocyte count (ALC) as predictor of Pneumocystis Jiroveci Pneumonia (PCP) infection in patients on immune checkpoint inhibitors (ICPi). (2019)
-
A novel prostate cancer immunotherapy using prostate-specific antigen peptides and <i>Candida</i> skin test reagent as an adjuvant (2018)
Grants & Funding
As listed on this researcher's institutional profile.
- Pfizer A7471009, A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small C Pfizer, Inc.
- Phase 2, Open-Label Single Arm Study of the Efficacy and Safety of PF-02341066 in Pfizer, Inc.
- Phase III, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Pa Pfizer, Inc.
- S1900C: A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study) (260760) NIH/Nat. Cancer Institute via SouthWest Oncology Group
- S1929, Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) (273385) Southwest Oncology Group-Clinical Trial Initiative
- A Phase 2, Randomized, Open Label Study of Figitumumab (CP-751,871) Plus Cisplatin (or Carboplatin) and Etoposide, Versus Cisplatin (or Carboplatin) a Pfizer, Inc.
- A randomized, open-label, Phase II, 2-arm multi-center trial comparing maintenance therapy with pazopanib or pemetrexed in non-progressing subjects wi GlaxoSmithKline
- A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamabin Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301) Amgen, Inc.
- An Open Label, Multi-center, IRESSA™ Clinical Access Program of Gefitinib 250 mg AstraZeneca
- An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunother Argos Therapeutics, Inc
- A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of Boehringer Ingleheim Pharmaceuticals, Inc.
- S1900G, “A Randomized Phase II Study of INC280 (capmatinib) plusOsimertinib with or without Ramucirumab in Participants with EGFR-Mutant, METAmplifiedStage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)” SouthWest Oncology Group
- Health Literacy and Emergency Preparedness Programs for Medicaid Recipients in Rural Arkansas US Department of Agriculture via University of Arkansas Division of Agriculture Cooperative Extension Service
- A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy versus Plac AbbVie Inc
- A Randomized, Open-label, Phase III Study to Evaluate the Efficacy and safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients Boehringer Ingleheim Bioproducts
- 297894: A Randomized Open-Label Phase 3 Study of Adjuvant Pembrolizumab With or Without MK-2870 in Patients With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Neoadjuvant Pembrolizumab Plus Platinum-Based Chemotherapy and Surgery Merck & Company, Inc.
- A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients receiving Sunitinib as First-Line Therapy for Ad Immatics Biotechnologies
- S2302, PRAGMATICA – LUNG: “A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV SouthWest Oncology Group
Collaboration Network
Top Collaborators
Matthew A. Steliga
University of Arkansas for Medical Sciences
3 shared publications
In database
- An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics
- Abstract 5038: Applying reproducible genomic data science methods for the analysis of a rare tumor type
- Incidentally Detected Pulmonary Carcinoid Tumorlet With Coexisting Carcinoid Tumorlet in the Mediastinal Lymph Node in a Patient With Lung Cancer
Omar Atiq
University of Arkansas for Medical Sciences (US)
3 shared publications
- Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench
- An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics
- Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care
Erich A. Peterson
Winthrop Rockefeller Foundation
2 shared publications
In database
- An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics
- Abstract 5038: Applying reproducible genomic data science methods for the analysis of a rare tumor type
Jason Muesse
University of Arkansas for Medical Sciences
2 shared publications
In database
- An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics
- Abstract 5038: Applying reproducible genomic data science methods for the analysis of a rare tumor type
Katy Marino
Winthrop Rockefeller Foundation
2 shared publications
In database
- An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics
- Abstract 5038: Applying reproducible genomic data science methods for the analysis of a rare tumor type
Donald J. Johann
Winthrop Rockefeller Foundation
2 shared publications
In database
- An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics
- Abstract 5038: Applying reproducible genomic data science methods for the analysis of a rare tumor type
Sunny Singh
University of Arkansas for Medical Sciences
2 shared publications
In database
- Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench
- Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care
Sindhu Janarthanam Malapati
University of Arkansas for Medical Sciences
2 shared publications
In database
- Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench
- Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care
Sajjad Akbar Bhatti
University of Arkansas for Medical Sciences
2 shared publications
In database
- Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench
- Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care
Issam Makhoul
University of Arkansas for Medical Sciences (US)
1 shared publication
- Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative
Michael Anders
University of Arkansas for Medical Sciences
1 shared publication
In database
- Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative
Robert D. Siegel
OSF Saint Francis Medical Center (US)
1 shared publication
- Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative
Anne C. Chiang
Yale Cancer Center (US)
1 shared publication
- Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative
Merry Jennifer Markham
Florida College (US)
1 shared publication
- Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative
Ronald C. Chen
The University of Kansas Cancer Center (US)
1 shared publication
- Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative
Similar Researchers
Based on overlapping research topics
Ebrahim Jakoet
University of Arkansas at Little Rock
Cancer-related molecular mechanisms research
Lung Cancer Diagnosis and Treatment
Genomics and Phylogenetic Studies
Saad A. Mahmoud
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Lung Cancer Diagnosis and Treatment
Disease Mechanisms Research
Charles M. Quick
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Medical Case Reports
Leonard Ferdman
Arkansas State University
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Disease Mechanisms Research
Malik Rettiganti
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Disease Mechanisms Research
Christina D. Miller
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Disease Mechanisms Research